Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Pfizer Inc. PFE

Healthcare  —  Drug Manufacturers General
28.67 0.26 0.92% as of 25 Sep
Market cap
$161.7B
P/E
37.7×
S&P 500 Member Dividend Champion (10y) Insider Buys (last 12m)
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Pfizer Inc. (PFE) EV/EBITDA

As of 25 September 2026, Pfizer Inc. (PFE) trades at a EV/EBITDA of 10.5×. Over the past ten years it has ranged from 5.7× (March 2023) to 55.3× (July 2024); the current reading is higher than 28% of that period. That is below the Drug Manufacturers General industry median of 13.9× and in line with the Healthcare sector median of 10.4×.

EV/EBITDA, daily

Annual

Period EV/EBITDA Change
FY2025 9.2× (7.46%)
FY2024 10.0× (66.67%)
FY2023 30.0× 307.57%
FY2022 7.4× (46.42%)
FY2021 13.7× (23.50%)
FY2020 17.9× (10.33%)
FY2019 20.0× (11.06%)
FY2018 22.5× 95.72%
FY2017 11.5× (4.20%)
FY2016 12.0× (0.47%)

Quarterly

Period EV/EBITDA Change
Jun 2026 9.3× (7.47%)
Mar 2026 10.0× 8.09%
Dec 2025 9.2× (1.45%)
Sep 2025 9.4× 8.86%
42 more quarters

Against its own ten years

Low 5.7× High 55.3×
Ten-year median 11.9×
Current reading's percentile 28

EV/EBITDA against peers

Company EV/EBITDA
NVO Novo Nordisk A/S compare 7.0×
GSK GSK PLC Sponsored ADR compare 9.3×
PFE Pfizer Inc. 10.5×
BMY Bristol Myers Squibb Company compare 10.6×
SNY Sanofi compare 11.2×
AZN AstraZeneca PLC compare 13.9×
NVS Novartis AG compare 14.0×
AMGN Amgen Inc. compare 16.2×
GILD Gilead Sciences, Inc. compare 804×
Drug Manufacturers General industry median 13.9×
Healthcare sector median 10.4×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on PFE